This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). Read More
Adults ages 18-85.
Have had a type of stroke called a large hemispheric infarction (LHI).
It is within 10 hours of onset of LHI.
This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More
Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).
This study enrolls adults with a common type of heart failure (called “preserved ejection fraction” or HFpEF) that has no proven treatment and is often the result of poorly controlled high blood pressure. The purpose of this study is to learn if the new investigational drug finerenone improves outcomes and is safe in patients with HFpEF. Read More
-Adults ages 40+.
-Diagnosed with heart failure (class II-IV).
This study enrolls adults who have been chosen to participate because they have carotid narrowing (a blockage) that may benefit from the use of the Neuroguard IEP System, a carotid stent and filter used during a medical procedure to open the blockage. Read More
-Adults ages 20-80.
-Have been diagnosed with carotid artery stenosis treatable with carotid artery stenting.
-Additional eligibility criteria apply.
This study enrolls adults who are scheduled to have an aortic valve replacement for disease the aortic valve called aortic stenosis. The Evolut PRO and Evolut PRO+ systems are FDA approved for treating aortic stenosis, so in this study we just want to collect data. The purpose of this study is to learn more about how well this device works. Read More
-Adults ages 18+.
-Have symptoms from aortic valve stenosis.
-Will be having aortic valve replacement.
This study enrolls people who have mitral regurgitation (MR). Mitral regurgitation happens when the heart’s mitral valve does not close tightly. The purpose of this trial is to evaluate a new investigational device called the Tendyne™ Mitral Valve System. The Tendyne Mitral Valve System is designed for the treatment of a diseased, damaged or malfunctioning mitral valve. This trial will collect information on how safe and effective this device is to treat a leaking mitral valve compared to the commercially available MitraClip® System. Read More
-Adults ages 18+.
-Have symptomatic, moderate-to-severe/severe mitral regurgitation (MR) or severe mitral annular calcification (MAC)
-Your medical providers have decided a transcatheter therapy is more appropriate than open surgery.
This study enrolls people who have had a stroke or who have epilepsy who are being seen at Buffalo General Hospital. We want to learn more about how a patient’s understanding of the disease, treatment and other factors prevent future medical events. Read More
Adults ages 18+.
Must have confirmed diagnosis of stroke or seizure disorder.
Presents for stroke or seizure at Buffalo General Medical Center.